- 24/7 Wall St.•2 days ago
The analysts at Merrill Lynch have raised their price targets on some stocks that have shown solid earnings growth and look poised to continue to deliver solid results for the rest of 2017.
- Investopedia•3 days ago
While Clovis lost $70.7 million, or $1.83 a share, in the latest 4Q, below analyst estimates.
- Zacks•3 days ago
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
CLVS : Summary for Clovis Oncology, Inc. - Yahoo Finance
Clovis Oncology, Inc. (CLVS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||57.71 x 100|
|Ask||58.00 x 100|
|Day's Range||56.56 - 59.33|
|52 Week Range||11.57 - 67.16|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.59|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|